Loading…
Loading grant details…
| Funder | Swedish Research Council |
|---|---|
| Recipient Organization | Karolinska Institutet |
| Country | Sweden |
| Start Date | Jul 01, 2023 |
| End Date | Jun 30, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2023-00291_VR |
The cell’s endogenous antioxidant system is critical for maintaining redox homeostasis.
The cytsine/glutamate antiporter, system xC-, controls the balance between intracellular reactive oxygen species and antioxidant production by providing cells with access to cystine, a critical amino acid in glutathione biosynthesis, in exchange for glutamate.
The restricted expression of system xC- in healthy tissue highlights the potential for non-invasive PET imaging of this dynamic process and enable increased understanding of oxidative stress, GSH biosynthesis, and glutamate secretion in a range of diseases such as cancer.
Despite the importance of system xC-, few specific radiopharmaceuticals have been reported, with often little knowledge regarding their cellular fate, tissue-specific properties and disease specificity.Dr.
Beinat’s group at Stanford University, California has recently pioneered the development of a homo-glutamate derivative labeled with fluorine-18 named [18F]hGTS13 as a novel radiotracer targeting system xC-.
The goal of the proposed project is to elucidate the cellular fate and specificity of [18F]hGTS13 in cancer compared to inflammation, as well as to determine the potential of [18F]hGTS13 for monitoring ferroptosis, a new distinct class of regulated cell death and posited to play a major role in cancer related tumor suppression.
Karolinska Institutet
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant